MRK Meets Endpoints
Merck's Tulisokibart meets primary and key secondary endpoints in Phase 3 ATLAS-UC induction-only study for ulcerative colitis
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.